These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 19256507)

  • 21. Orally active PDE4 inhibitors with therapeutic potential.
    Ochiai H; Ohtani T; Ishida A; Kishikawa K; Obata T; Nakai H; Toda M
    Bioorg Med Chem Lett; 2004 Mar; 14(5):1323-7. PubMed ID: 14980691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An oral phosphodiesterase inhibitor (apremilast) for inflammatory rosacea in adults: a pilot study.
    Thompson BJ; Furniss M; Zhao W; Chakraborty B; Mackay-Wiggan J
    JAMA Dermatol; 2014 Sep; 150(9):1013-4. PubMed ID: 25054629
    [No Abstract]   [Full Text] [Related]  

  • 23. Discovery of a highly potent series of oxazole-based phosphodiesterase 4 inhibitors.
    Kuang R; Shue HJ; Blythin DJ; Shih NY; Gu D; Chen X; Schwerdt J; Lin L; Ting PC; Zhu X; Aslanian R; Piwinski JJ; Xiao L; Prelusky D; Wu P; Zhang J; Zhang X; Celly CS; Minnicozzi M; Billah M; Wang P
    Bioorg Med Chem Lett; 2007 Sep; 17(18):5150-4. PubMed ID: 17683932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of selective PDE4B inhibitors.
    Naganuma K; Omura A; Maekawara N; Saitoh M; Ohkawa N; Kubota T; Nagumo H; Kodama T; Takemura M; Ohtsuka Y; Nakamura J; Tsujita R; Kawasaki K; Yokoi H; Kawanishi M
    Bioorg Med Chem Lett; 2009 Jun; 19(12):3174-6. PubMed ID: 19447034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor.
    Chen C; Wu D; Guo Z; Xie Q; Reinhart GJ; Madan A; Wen J; Chen T; Huang CQ; Chen M; Chen Y; Tucci FC; Rowbottom M; Pontillo J; Zhu YF; Wade W; Saunders J; Bozigian H; Struthers RS
    J Med Chem; 2008 Dec; 51(23):7478-85. PubMed ID: 19006286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase.
    Goldstein DM; Alfredson T; Bertrand J; Browner MF; Clifford K; Dalrymple SA; Dunn J; Freire-Moar J; Harris S; Labadie SS; La Fargue J; Lapierre JM; Larrabee S; Li F; Papp E; McWeeney D; Ramesha C; Roberts R; Rotstein D; San Pablo B; Sjogren EB; So OY; Talamas FX; Tao W; Trejo A; Villasenor A; Welch M; Welch T; Weller P; Whiteley PE; Young K; Zipfel S
    J Med Chem; 2006 Mar; 49(5):1562-75. PubMed ID: 16509574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between phosphodiesterase type 4 inhibition and anti-inflammatory activity of CI-1044 in rat airways.
    Pruniaux MP; Lagente V; Ouaged M; Bertin B; Moreau F; Julien-Larose C; Rocher MN; Leportier C; Martin B; Bouget A; Dubuit JP; Burnouf C; Doherty AM; Bertrand CP
    Fundam Clin Pharmacol; 2010 Feb; 24(1):73-82. PubMed ID: 19650853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast.
    Gooderham M; Papp K
    BioDrugs; 2015 Oct; 29(5):327-39. PubMed ID: 26481941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo.
    Griswold DE; Webb EF; Badger AM; Gorycki PD; Levandoski PA; Barnette MA; Grous M; Christensen S; Torphy TJ
    J Pharmacol Exp Ther; 1998 Nov; 287(2):705-11. PubMed ID: 9808700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one.
    Hughes RO; Walker JK; Rogier DJ; Heasley SE; Blevis-Bal RM; Benson AG; Jacobsen EJ; Cubbage JW; Fobian YM; Owen DR; Freskos JN; Molyneaux JM; Brown DL; Acker BA; Maddux TM; Tollefson MB; Moon JB; Mischke BV; Rumsey JM; Zheng Y; MacInnes A; Bond BR; Yu Y
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5209-13. PubMed ID: 19631533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thalidomide metabolites and analogues. 3. Synthesis and antiangiogenic activity of the teratogenic and TNFalpha-modulatory thalidomide analogue 2-(2,6-dioxopiperidine-3-yl)phthalimidine.
    Luzzio FA; Mayorov AV; Ng SS; Kruger EA; Figg WD
    J Med Chem; 2003 Aug; 46(18):3793-9. PubMed ID: 12930142
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pyrazolopyridines as potent PDE4B inhibitors: 5-heterocycle SAR.
    Mitchell CJ; Ballantine SP; Coe DM; Cook CM; Delves CJ; Dowle MD; Edlin CD; Hamblin JN; Holman S; Johnson MR; Jones PS; Keeling SE; Kranz M; Lindvall M; Lucas FS; Neu M; Solanke YE; Somers DO; Trivedi NA; Wiseman JO
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5803-6. PubMed ID: 20732811
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phosphodiesterase-4 inhibitors: a review of current developments (2010 - 2012).
    Gavaldà A; Roberts RS
    Expert Opin Ther Pat; 2013 Aug; 23(8):997-1016. PubMed ID: 23642007
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.
    Corral LG; Haslett PA; Muller GW; Chen R; Wong LM; Ocampo CJ; Patterson RT; Stirling DI; Kaplan G
    J Immunol; 1999 Jul; 163(1):380-6. PubMed ID: 10384139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor.
    Bundschuh DS; Eltze M; Barsig J; Wollin L; Hatzelmann A; Beume R
    J Pharmacol Exp Ther; 2001 Apr; 297(1):280-90. PubMed ID: 11259555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 2: metabolism-directed optimization studies towards orally bioavailable derivatives.
    Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Ducrot P; Wrigglesworth R; Berlioz-Seux F; Coleon F; Chevalier E; Moreau F; Idrissi M; Tertre A; Descours A; Berna P; Li M
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4615-21. PubMed ID: 15324875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis, and biological evaluation of 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a potent, orally active, brain penetrant inhibitor of phosphodiesterase 5 (PDE5).
    Hughes RO; Rogier DJ; Jacobsen EJ; Walker JK; Macinnes A; Bond BR; Zhang LL; Yu Y; Zheng Y; Rumsey JM; Walgren JL; Curtiss SW; Fobian YM; Heasley SE; Cubbage JW; Moon JB; Brown DL; Acker BA; Maddux TM; Tollefson MB; Mischke BV; Owen DR; Freskos JN; Molyneaux JM; Benson AG; Blevis-Bal RM
    J Med Chem; 2010 Mar; 53(6):2656-60. PubMed ID: 20196613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacology of a potent and selective inhibitor of PDE4 for inhaled administration.
    Chapman RW; House A; Richard J; Prelusky D; Lamca J; Wang P; Lundell D; Wu P; Ting PC; Lee JF; Aslanian R; Phillips JE
    Eur J Pharmacol; 2010 Sep; 643(2-3):274-81. PubMed ID: 20621091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of novel 1,4-dihydropyridine-based PDE4 inhibitors.
    Poondra RR; Nallamelli RV; Meda CL; Srinivas BN; Grover A; Muttabathula J; Voleti SR; Sridhar B; Pal M; Parsa KV
    Bioorg Med Chem Lett; 2013 Feb; 23(4):1104-9. PubMed ID: 23294698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. KR-003048, a potent, orally active inhibitor of p38 mitogen-activated protein kinase.
    Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst J; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
    Eur J Pharmacol; 2010 Apr; 632(1-3):93-102. PubMed ID: 20132813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.